STOCK TITAN

Medtronic plc - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.

Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.

The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.

In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).

Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.

Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.

Rhea-AI Summary

On March 9, 2022, Medtronic (NYSE: MDT) announced a contract with Vizient to integrate Touch Surgery Enterprise, an AI-powered surgical video management platform, into Vizient’s offerings. This platform enhances surgical training and performance by simplifying the recording, analysis, and sharing of surgical videos. It connects with existing OR equipment and supports hospitals in digitizing their processes. The agreement aims to provide nationwide access to surgical video data, enabling improved patient care and operational efficiencies across U.S. healthcare facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary

The board of directors of Medtronic plc (NYSE:MDT) has approved a cash dividend of $0.63 per ordinary share for Q4 of fiscal year 2022, marking an 8.6% increase from the previous year. This dividend aligns with the company's commitment to returning value to shareholders, maintaining its status as an S&P 500 Dividend Aristocrat with a continuous annual dividend increase for 44 years. The dividend is set to be paid on April 22, 2022, to shareholders on record by March 25, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
dividends earnings
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced its participation in the 42nd annual Cowen healthcare conference on March 7, 2022. The event will feature Karen Parkhill, Medtronic's executive vice president and CFO, who will engage in a Q&A session starting at 1:30 p.m. EST (12:30 p.m. CST). A live webcast of this session will be available on Medtronic's investor relations website, with an archive accessible later that day. Medtronic is a global leader in healthcare technology, addressing major health challenges with innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences
Rhea-AI Summary

Medtronic plc (NYSE: MDT) has launched the NuVent™ Eustachian tube dilation balloon, approved by the FDA for treating chronic obstructive Eustachian Tube Dysfunction. This innovative product allows outpatient treatment through its customizable and flexible design. Eustachian Tube Dysfunction affects approximately 4.6% of U.S. adults, causing pain and hearing issues. The NuVent™ balloon offers a minimally invasive solution that improves patient convenience and outcomes, as highlighted by medical experts. Medtronic continues to expand its portfolio for ENT procedures, addressing significant healthcare challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE:MDT) has received FDA approval for the InterStim X, a rechargeable device designed for sacral neuromodulation therapy, now available for patients. This system, part of the InterStim portfolio, boasts over 10 years of battery life without recharging, enhancing patient convenience. Backed by 90+ clinical studies and treating over 350,000 patients, the InterStim X is a significant advancement for conditions like overactive bladder and fecal incontinence. This release marks a pivotal milestone as Medtronic celebrates 25 years of innovation in nerve stimulation therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
-
Rhea-AI Summary

Medtronic (NYSE: MDT) has partnered with the American Society for Gastrointestinal Endoscopy (ASGE) to enhance colorectal cancer screening in low-income communities through the Health Equity Assistance Program. The initiative will donate 50 GI Genius™ intelligent endoscopy modules to endoscopy centers, potentially benefiting over 350,000 patients over three years. Colorectal cancer, a major health concern, can have a 91% five-year survival rate if detected early. This program aims to address significant disparities in screening access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
Rhea-AI Summary

Medtronic plc (NYSE: MDT) reported Q3 fiscal 2022 results with revenue of $7.763 billion, flat year-over-year but up 2% organically. GAAP diluted EPS rose 17% to $1.10, while non-GAAP diluted EPS increased 6% to $1.37. The U.S. revenue was $3.939 billion (51% of total), remaining flat, while international revenue saw mixed results: down 3% in developed markets but up 5% in emerging markets. The company anticipates Q4 organic revenue growth of 5.5% and EPS guidance between $1.56 to $1.58, reflecting ongoing recovery from COVID-19 impacts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
-
Rhea-AI Summary

Medtronic (NYSE:MDT) announced FDA approval for its Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters, the first devices approved to treat pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT), a common and life-threatening heart rhythm disorder affecting 89,000 individuals annually, with 35% being children. These catheters, utilized in catheter ablation therapy, boast a 95% procedural success rate without permanent pacemaker requirements. Medtronic has successfully treated over 140,000 patients globally with its cryoablation technology, demonstrating its efficacy and safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE:MDT) will report its financial results for Q3 FY2022 on February 22, 2022, at 5:45 a.m. CST. A video webcast will follow at 7:00 a.m. CST to discuss these results. The financial results will cover the quarter ending January 28, 2022. Looking ahead, Medtronic plans to announce its Q4 and full FY2022 results on May 26, 2022, and provide future earnings report dates for FY2023 later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
Rhea-AI Summary

Medtronic plc (NYSE:MDT) and OLV Hospital Aalst announced the first clinical procedure in Europe using the Hugo™ robotic-assisted surgery (RAS) system, performed by Dr. Alexandre Mottrie. This significant milestone showcases advances in minimally invasive surgery, which offers benefits like fewer complications and shorter recovery times. The Hugo RAS system aims to enhance accessibility to surgical robotics. As a part of its global rollout, Medtronic plans to collect clinical data from procedures in Europe, further supporting future regulatory submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none

FAQ

What is the current stock price of Medtronic plc (MDT)?

The current stock price of Medtronic plc (MDT) is $86.21 as of November 22, 2024.

What is the market cap of Medtronic plc (MDT)?

The market cap of Medtronic plc (MDT) is approximately 109.1B.

What does Medtronic plc specialize in?

Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools.

Where are Medtronic’s headquarters located?

Medtronic’s operational and executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Dublin, Ireland, following its acquisition of Covidien in 2015.

How significant are Medtronic’s international sales?

International sales account for roughly 50% of Medtronic’s total revenue.

What recent advancements has Medtronic made in AI for healthcare?

Medtronic recently launched the ColonPRO™ software for the GI Genius™ intelligent endoscopy system, enhancing AI-driven polyp detection and procedural highlights. The company also partnered with Modernizing Medicine® to integrate AI data with EHR systems.

What are Medtronic’s recent financial achievements?

Medtronic reported a global revenue of $32.364 billion for fiscal year 2024, a 3.6% increase from the previous year, driven by growth in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

What new technology has Medtronic introduced for chronic pain treatment?

Medtronic introduced the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), which the U.S. FDA approved for the treatment of chronic pain.

How many employees does Medtronic have worldwide?

Medtronic has a global team of over 95,000 employees across 150 countries.

What is Medtronic’s mission?

Medtronic's mission is to alleviate pain, restore health, and extend life.

Where can I find more information about Medtronic?

For more information about Medtronic, visit their official website at Medtronic.com.

How does Medtronic approach innovation in healthcare?

Medtronic leverages its diverse knowledge, insatiable curiosity, and commitment to helping those in need to deliver innovative technologies that transform lives, focusing on engineering extraordinary healthcare solutions.

Medtronic plc

NYSE:MDT

MDT Rankings

MDT Stock Data

109.06B
1.28B
0.26%
85.42%
0.79%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GALWAY